Table 3. Distribution of the HLA class I KIR-ligands in in patients with and without ocular toxoplasmosis and its primary or recurrent manifestations.
| HLA ligands* | Patients without ocular toxoplasmosis (n = 149) | Patients with ocular toxoplasmosis (n = 148) | Patients with primary manifestation (n = 120) | Patients with recurrent manifestation (n = 28) |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | |
| A3 and/or A11 | 31 (20.8) | 42 (28.4) | 32 (26.7) | 10 (35.7) |
| Bw4 | 113 (75.8) | 104 (70.3) | 84 (70.0) | 20 (71.4) |
| Bw4-80Ile | 93 (62.4) | 87 (58.8) | 72 (60.0) | 15 (53.6) |
| Bw4-80Thr | 46 (30.9) | 39 (26.4) | 29 (24.2) | 10 (35.7) |
| C1C2 | 62 (41.6) | 58 (39.2) | 46 (38.3) | 12 (42.9) |
| C1C1 | 26 (17.4) | 25 (16.9) | 19 (15.8) | 6 (21.4) |
| C2C2 | 61 (40.9) | 65 (43.9) | 55 (45.8) | 10 (35.7) |
Bw4 = HLA-A*23, *24, *32; HLA-B *13, *27, *44, *51, *52, *53, *57, *58. Bw4-80Ile = HLA-A*23, *24, *32; HLA-B*51, *52, *53, *57, *58. Bw4-80Thr = HLA-B *13, *27, *44. Group C1 = HLA-C*01, *03, *07, *08, *12, *14, *16. Group C2 = HLA-C*02, *04, *05, *06, *07, *15, *17, *18. *The same individual could express more than one pair KIR-HLA ligand.